health
Phase 2 lung cancer trial tests durvalumab before surgery or chemoradiotherapy
In the single-arm MDT-BRIDGE phase 2 study, 142 people with resectable or borderline resectable non-small-cell lung cancer received durvalumab plus chemotherapy before multidisciplinary teams directed them to surgery or chemoradiotherapy. Surgery was performed in 74.6%; survival follow-up is still early.